Home » AstraZeneca Escapes Medco FCA Kickbacks Suit

AstraZeneca Escapes Medco FCA Kickbacks Suit

January 28, 2013

Citing a lack of jurisdiction, a Pennsylvania federal judge on Friday dismissed AstraZeneca from a False Claims Act whistleblower suit brought by a former Medco Health Solutions pharmacist who claims AstraZeneca gave Medco $60 million in kickbacks to increase the market share of ulcer drugs Prilosec and Nexium.
Law360

10Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

AstraZeneca Escapes Medco FCA Kickbacks Suit

Upcoming Events

Gene & Cell Therapy Regulation: Comparability and Other New Developments

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Hyris T-Cell Test Gains CE-IVD Mark

FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements